$$$MEGA NEWS BEI GENEREX$$$ - 500 Beiträge pro Seite

[Shawn30]

Das wird Heute in den USA zu einer enormen Rallye führen!

Generex Biotechnology Announces Pre-NDS Meeting Scheduled for Generex Oral-lyn(TM) With Health Canada Company Will Seek to File a New Drug Submission in Order to Market and Distribute Generex Oral-lyn in Canada

TORONTO, Jan 19, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has received notification of the scheduling of a Pre-NDS meeting for the Company with the Biologics and Genetic Therapies Directorate of Health Canada on March 1, 2006. The topic of the meeting will be Generex Oral-lyn, the Company`s proprietary buccal (oral) insulin spray product (no lung deposition). The Company believes this is the first non-injectable insulin to be the subject of a Pre-NDS meeting.
The purpose of the Pre-NDS meeting will be to discuss the presentation of Generex Oral-lyn data in support of a New Drug Submission (NDS). An NDS is an application submitted to Health Canada in order to market and distribute a drug product in Canada. Such applications are generally filed after clinical trials have been completed and all data has been collected and analyzed. This process is similar to a Pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company`s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company`s proprietary RapidMist(TM) device. The Company`s flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

[Coolbleiben]

Sali Shawn

Ich mag mich noch sehr gut erinnern, am 11.1.06 hast du diese Aktie bei ca. Euro 0.95 zum Kauf empfohlen............................, seither ist der Kurs stark gefallen.........


Grüsse aus Zürich

[Shawn30]

[posting]19.785.526 von Coolbleiben am 19.01.06 15:05:05[/posting]Ich habe die Aktie nicht bei 0,95€ empfohlen.

Nach meiner Empfehlung haben nur einige den Kurs hier in D bis auf 1,00€ getrieben.

Wobei in dem Thread klar darauf hingewiesen wurde lieber in den USA zu kaufen.

Tortzdem werden selbst die die bei 0,95€ gekauft haben in Kürze fett im plus sein.

[therman]

Im thread zu GBNT wurden diese news schon erwähnt,
und weitere interessante INFOS.

Thread: GENEREX: EIN MILLIARDENMARKT!!!!

[Tiger_im_Glueck]

[posting]19.785.692 von Shawn30 am 19.01.06 15:13:38[/posting]Ich kann die Wertigkeit der Meldung noch nicht richtig einschätzen. Kannst Du dazu noch kurz etwas schreiben?

[Aktientrade]

legt euch lieber ein paar nevada pacific ins depot!

grund steht im thread zu der aktie!

ich sage nur: 23.1.06

[gehtsjetztendlich]

habe meine 2k heute gegeben zu 1,04€ / KK 0,76€
Gier frißt Hirn.....